Webinar replay

Due Diligence: What’s Now and What’s Next

Strong due diligence requires the right subject matter experts, strong processes, proper data and knowledge management. Yet while the fundamentals remain, due diligence teams are increasingly challenged to respond to new trends, embrace new technologies, and accelerate their reporting. 

Mike Myers, Associate Vice President, LRL – Due Diligence at Eli Lilly & Company, and William Vickery, Due Diligence Director at Servier, join Inova to explore best practices in biopharma due diligence in 2023. From today’s post-pandemic praxes to emerging trends such as assessing carbon emissions and the impact of artificial intelligence, and the differences between due diligence for licensing and acquisitions, Myers and Vickery will share their decades of experience in biopharma partnering in this exclusive Inova webinar. 

Watch this replay to get expert insights from our panelists:
Mike Myers
Associate Vice President, LRL – Due Diligence
Eli Lilly & Company
William Vickery
Due Diligence Director

Please complete the form below

All fields marked with a * are required.

By submitting this form, you agree to the storing and processing of your
personal data by Inova as detailed in the Privacy Statement.

About Inova

Inova accelerates the find, deal, and collaborate phases of biopharma partnering. Its market-leading platform is used by 60% of the world’s top 50 pharma companies to source and manage their opportunities efficiently, and its technology powers more than 50,000 partnering meetings each year at the world's most important biopharma partnering conferences, including the BIO International Convention.
With subsidiaries Labiotech and IN-PART, Inova reaches more than 100,000 readers in life sciences a month and connects a network of 6,500 industry players and academic organizations.